Abby M. Kelly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abby M. Kelly has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Anthony J. Convertine
Department of Materials Science and Engineering, Missouri University of Science and Technology, 1400 North Bishop Avenue, Rolla, MO 65409, USA
4 shared publications - Patrick Stayton
Department of Bioengineering, University of Washington, Seattle, WA 98195, USA
4 shared publications David Jones
University of Nebraska, Lincoln
3 shared publicationsDaniel M. Ratner
Department of Bioengineering, University of Washington , Seattle, Washington 98195, United States
2 shared publicationsDebobrato Das
Department of Bioengineering, University of Washington , Seattle, Washington 98195, United States
2 shared publicationsDennis D. Schulte
University of Nebraska, Lincoln
2 shared publications
Latest Publications
- 11 September 2020
- Published by American Society for Engineering Education
- p. 25.192.1-25.192.12
Application of Data Management Tools for ABET Accreditation
Application of data management tools for ABET accreditation A task of the ABET accreditation process is to have documented student outcomes thatprepare students to attain program educational objectives. Traditionally, evidence for individualsis stored in a hard copy sampling of student work. However, the advent of electronic documentconversion and database management enables the ability to readily prepare documents forcontinuous assessment. Recently, two data management and assessment tools were created andapplied for documenting student outcomes for courses within each engineering program. Togenerate documentation, evidence included course syllabi, lecture notes, and oral presentationsof design projects all saved or converted to an electronic format. Once evidence was compiledinto a database containing student outcomes for each course, the evidence was given acompetency rating based on Bloom’s taxonomy. Following an assessment of achievement basedon evidence, the course target for each student outcome was assessed using the gap analysis tool.The tool compared the target student outcomes of each course and related them to the outcomesindicated by the evidence. This relation was able to demonstrate whether an instructor was overor under achieving the intended student outcomes for the course. The purpose of this paper is toshowcase the application of these data management tools for use in evidence collection andcurriculum assessment for both agricultural and biological engineering programs.
- 11 September 2020
- Published by American Society for Engineering Education
- p. 25.192.1-25.192.12
Application of Data Management Tools for ABET Accreditation
Application of data management tools for ABET accreditation A task of the ABET accreditation process is to have documented student outcomes thatprepare students to attain program educational objectives. Traditionally, evidence for individualsis stored in a hard copy sampling of student work. However, the advent of electronic documentconversion and database management enables the ability to readily prepare documents forcontinuous assessment. Recently, two data management and assessment tools were created andapplied for documenting student outcomes for courses within each engineering program. Togenerate documentation, evidence included course syllabi, lecture notes, and oral presentationsof design projects all saved or converted to an electronic format. Once evidence was compiledinto a database containing student outcomes for each course, the evidence was given acompetency rating based on Bloom’s taxonomy. Following an assessment of achievement basedon evidence, the course target for each student outcome was assessed using the gap analysis tool.The tool compared the target student outcomes of each course and related them to the outcomesindicated by the evidence. This relation was able to demonstrate whether an instructor was overor under achieving the intended student outcomes for the course. The purpose of this paper is toshowcase the application of these data management tools for use in evidence collection andcurriculum assessment for both agricultural and biological engineering programs.
- 11 September 2020
- Published by American Society for Engineering Education
- p. 25.461.1-25.461.14
Development of Evidence Management and Gap Analysis Tools for Continuous Improvement of Engineering Programs
Development of evidence management and gap analysis tools for continuous improvement of engineering programs The purpose of this paper is to demonstrate the development and structure of recentlycreated data management tools used to assist in the continuous improvement of both anagricultural and biological engineering program. With the arrival of automatic document feederscapable of transforming paper materials in electronic documents, evidence of course contributionto student outcomes is easier to map than ever before. Additionally, electronic storage enablesthe ability to search within documents and connect related data more effectively than could beachieved with paper documentation. As a result, the following paper includes the development ofkey components for establishing relationships between course evidence (student work, syllabi,etc.) and student outcomes, a critical component of criterion 3 of the general criteria forbaccalaureate level programs seeking ABET accreditation. Furthermore, the developed structureincludes a means for collecting data and correlating the evidence to specific ABET a-k studentoutcomes in combination with a modified Bloom’s taxonomy for classifying competency. In addition to evidence collection and classification of course student outcomes, thedesign of a gap analysis tool for relating targeted student outcome levels with each course’sachieved student outcomes will also be discussed. The function of the gap analysis tool is toinform instructors as to whether a course, based on the supplied evidence, is under or overachieving its specified target of student outcome performance. These tools were recently used foran ABET accreditation cycle and have the potential to be powerful resources for programshoping to close the loop as part of their continuous improvement process. In summary, this paperwill demonstrate the development of a database tool implement for capturing, reviewing, andassessing student output on a course by course basis.
- 11 September 2020
- Published by American Society for Engineering Education
- p. 25.461.1-25.461.14
Development of Evidence Management and Gap Analysis Tools for Continuous Improvement of Engineering Programs
Development of evidence management and gap analysis tools for continuous improvement of engineering programs The purpose of this paper is to demonstrate the development and structure of recentlycreated data management tools used to assist in the continuous improvement of both anagricultural and biological engineering program. With the arrival of automatic document feederscapable of transforming paper materials in electronic documents, evidence of course contributionto student outcomes is easier to map than ever before. Additionally, electronic storage enablesthe ability to search within documents and connect related data more effectively than could beachieved with paper documentation. As a result, the following paper includes the development ofkey components for establishing relationships between course evidence (student work, syllabi,etc.) and student outcomes, a critical component of criterion 3 of the general criteria forbaccalaureate level programs seeking ABET accreditation. Furthermore, the developed structureincludes a means for collecting data and correlating the evidence to specific ABET a-k studentoutcomes in combination with a modified Bloom’s taxonomy for classifying competency. In addition to evidence collection and classification of course student outcomes, thedesign of a gap analysis tool for relating targeted student outcome levels with each course’sachieved student outcomes will also be discussed. The function of the gap analysis tool is toinform instructors as to whether a course, based on the supplied evidence, is under or overachieving its specified target of student outcome performance. These tools were recently used foran ABET accreditation cycle and have the potential to be powerful resources for programshoping to close the loop as part of their continuous improvement process. In summary, this paperwill demonstrate the development of a database tool implement for capturing, reviewing, andassessing student output on a course by course basis.
- 4 September 2020
- Published by American Society for Engineering Education
- p. 23.697.1-23.697.20
Implementation of a “Rapid Design Challenge” in a Cross-Disciplinary Senior Capstone Course and Evaluation of Device Performance
Implementation of a “Rapid Design Challenge” in a Cross-Disciplinary Senior Capstone Course and Evaluation of Device PerformanceWithin the Department of Biological Systems Engineering at the University of Nebraska-Lincoln, the senior capstone course sequence, AGEN/BSEN 470/480, is a two-semester longcourse (4 credit hours total, seniors only) designed to give students real-life design experience,working with real projects, real clients, faculty consultants, and teammates to produce adeliverable that suits the client’s needs. Students within this course sequence come from twodifferent degree programs (agricultural engineering and biological systems engineering) andwithin each degree program from a variety of “emphasis areas”, e.g. biomedical engineering,environmental engineering, machine design. While the goal of this course is for the students toexperience a “real” design project, we felt that we need to improve this senior design sequencewith an exercise that forced all students through a shared and “complete” design process.Therefore, beginning in 2010, we implement a two-week, rapid design challenge at the beginningof the AGEN/BESN 470 senior design experience, based on a similar challenge developed atBucknell University (Tranquillo, 2009, ASEE Proceedings). This abbreviated design experiencechallenges the students to rapidly learn and implement the basic steps of design to produce afunctional prototype, which is displayed and tested during a design challenge contest. Thechallenge presented to students is to design and build a device for a third-world clinic to infuse acholera treatment solution, at a very specific flow rate and time for injection, with technicalconstraints that the device cannot use an external power source, must be portable and oncestarted must operate without any manual intervention. During this two week challenge, sixdifferent assignments are due, moving the students through the design process and guiding themto develop a problem statement, technical specifications, user needs, alternative solutions, testingprocedures and data, and a final solution. Teams are given $25 to build their device and time totest and reiterate their design before a final competition between teams. They are alsoencouraged to keep their design confidential from other teams. The team with a device that mostclosely achieves the dictated criteria (60 cc of solution delivered in 5 minutes at a constant flowrate of 12 cc/min) wins the competition. As a part of this challenge we have developed a systemto evaluate the performance of each design using a National Instruments (NI) data acquisitionsystem, NI LabView software and two Micro Motion coriolis flow measuring devices. Asidefrom the flow measurement itself, the software continuously calculates and displays the averageflow rate, the standard deviation of the flow rate, and the delivery time. When all of thetreatment has been administered, the software calculates a score based on flow accuracy andprecision. Scores are combined with faculty judge evaluations within the LabView program anddisplayed throughout the competition. This exercise has revitalized the course and ensured thatall students share a common and successful design experience. In addition, we then use theRapid Design Challenge to introduce all future topics in the course.
- 4 September 2020
- Published by American Society for Engineering Education
- p. 23.697.1-23.697.20
Implementation of a “Rapid Design Challenge” in a Cross-Disciplinary Senior Capstone Course and Evaluation of Device Performance
Implementation of a “Rapid Design Challenge” in a Cross-Disciplinary Senior Capstone Course and Evaluation of Device PerformanceWithin the Department of Biological Systems Engineering at the University of Nebraska-Lincoln, the senior capstone course sequence, AGEN/BSEN 470/480, is a two-semester longcourse (4 credit hours total, seniors only) designed to give students real-life design experience,working with real projects, real clients, faculty consultants, and teammates to produce adeliverable that suits the client’s needs. Students within this course sequence come from twodifferent degree programs (agricultural engineering and biological systems engineering) andwithin each degree program from a variety of “emphasis areas”, e.g. biomedical engineering,environmental engineering, machine design. While the goal of this course is for the students toexperience a “real” design project, we felt that we need to improve this senior design sequencewith an exercise that forced all students through a shared and “complete” design process.Therefore, beginning in 2010, we implement a two-week, rapid design challenge at the beginningof the AGEN/BESN 470 senior design experience, based on a similar challenge developed atBucknell University (Tranquillo, 2009, ASEE Proceedings). This abbreviated design experiencechallenges the students to rapidly learn and implement the basic steps of design to produce afunctional prototype, which is displayed and tested during a design challenge contest. Thechallenge presented to students is to design and build a device for a third-world clinic to infuse acholera treatment solution, at a very specific flow rate and time for injection, with technicalconstraints that the device cannot use an external power source, must be portable and oncestarted must operate without any manual intervention. During this two week challenge, sixdifferent assignments are due, moving the students through the design process and guiding themto develop a problem statement, technical specifications, user needs, alternative solutions, testingprocedures and data, and a final solution. Teams are given $25 to build their device and time totest and reiterate their design before a final competition between teams. They are alsoencouraged to keep their design confidential from other teams. The team with a device that mostclosely achieves the dictated criteria (60 cc of solution delivered in 5 minutes at a constant flowrate of 12 cc/min) wins the competition. As a part of this challenge we have developed a systemto evaluate the performance of each design using a National Instruments (NI) data acquisitionsystem, NI LabView software and two Micro Motion coriolis flow measuring devices. Asidefrom the flow measurement itself, the software continuously calculates and displays the averageflow rate, the standard deviation of the flow rate, and the delivery time. When all of thetreatment has been administered, the software calculates a score based on flow accuracy andprecision. Scores are combined with faculty judge evaluations within the LabView program anddisplayed throughout the competition. This exercise has revitalized the course and ensured thatall students share a common and successful design experience. In addition, we then use theRapid Design Challenge to introduce all future topics in the course.
- 15 May 2018
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 6 (7) , 1976-1985
Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections
Pulmonary intracellular infections, such as tuberculosis, anthrax, and tularemia, have remained a significant challenge to conventional antibiotic therapy. Ineffective antibiotic treatment of these infections can lead not only to undesired side effects, but also to the emergence of antibiotic resistance. Aminoglycosides (e.g., streptomycin) have long been part of the therapeutic regiment for many pulmonary intracellular infections. Their bioavailability for intracellular bacterial pools, however, is limited by poor membrane permeability and rapid elimination. To address this challenge, polymer-augmented liposomes (PALs) were developed to provide improved cytosolic delivery of streptomycin to alveolar macrophages, an important host cell for intracellular pathogens. A multifunctional diblock copolymer was engineered to functionalize PALs with carbohydrate-mediated targeting, pH-responsive drug release, and endosomal release activity with a single functional polymer that replaces the pegylated lipid component to simplify the liposome formulation. The pH-sensing functionality enabled PALs to provide enhanced release of streptomycin under endosomal pH conditions (70% release in 6 hours) with limited release at physiological pH 7.4 (16%). The membrane-destabilizing activity connected to endosomal release was characterized in a hemolysis assay and PALs displayed a sharp pH profile across the endosomal pH development target range. The direct connection of this membrane-destabilizing pH profile to model drug release was demonstrated in an established pyranine/p-xylene bispyridinium dibromide (DPX) fluorescence dequenching assay. PALs displayed similar sharp pH-responsive release, whereas PEGylated control liposomes did not, and similar profiles were then shown for streptomycin release. The mannose-targeting capability of the PALs was also demonstrated with 2.5 times higher internalization compared to non-targeted PEGylated liposomes. Finally, the streptomycin-loaded PALs were shown to have a significantly improved intracellular antibacterial activity in a Francisella-macrophage co-culture model, compared with free streptomycin or streptomycin delivered by control PEGylated liposomes (13× and 16×, respectively). This study suggests the potential of PALs as a useful platform to deliver antibiotics for the treatment of intracellular macrophage infections.
- 15 May 2018
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 6 (7) , 1976-1985
Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections
Pulmonary intracellular infections, such as tuberculosis, anthrax, and tularemia, have remained a significant challenge to conventional antibiotic therapy. Ineffective antibiotic treatment of these infections can lead not only to undesired side effects, but also to the emergence of antibiotic resistance. Aminoglycosides (e.g., streptomycin) have long been part of the therapeutic regiment for many pulmonary intracellular infections. Their bioavailability for intracellular bacterial pools, however, is limited by poor membrane permeability and rapid elimination. To address this challenge, polymer-augmented liposomes (PALs) were developed to provide improved cytosolic delivery of streptomycin to alveolar macrophages, an important host cell for intracellular pathogens. A multifunctional diblock copolymer was engineered to functionalize PALs with carbohydrate-mediated targeting, pH-responsive drug release, and endosomal release activity with a single functional polymer that replaces the pegylated lipid component to simplify the liposome formulation. The pH-sensing functionality enabled PALs to provide enhanced release of streptomycin under endosomal pH conditions (70% release in 6 hours) with limited release at physiological pH 7.4 (16%). The membrane-destabilizing activity connected to endosomal release was characterized in a hemolysis assay and PALs displayed a sharp pH profile across the endosomal pH development target range. The direct connection of this membrane-destabilizing pH profile to model drug release was demonstrated in an established pyranine/p-xylene bispyridinium dibromide (DPX) fluorescence dequenching assay. PALs displayed similar sharp pH-responsive release, whereas PEGylated control liposomes did not, and similar profiles were then shown for streptomycin release. The mannose-targeting capability of the PALs was also demonstrated with 2.5 times higher internalization compared to non-targeted PEGylated liposomes. Finally, the streptomycin-loaded PALs were shown to have a significantly improved intracellular antibacterial activity in a Francisella-macrophage co-culture model, compared with free streptomycin or streptomycin delivered by control PEGylated liposomes (13× and 16×, respectively). This study suggests the potential of PALs as a useful platform to deliver antibiotics for the treatment of intracellular macrophage infections.
- 16 August 2017
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 11 (9) , 8600-8611
Core-Cross-Linked Nanoparticles Reduce Neuroinflammation and Improve Outcome in a Mouse Model of Traumatic Brain Injury
Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults, yet there are currently no treatments available that prevent the secondary spread of damage beyond the initial insult. The chronic progression of this secondary injury is in part caused by the release of reactive oxygen species (ROS) into surrounding normal brain. Thus, treatments that can enter the brain and reduce the spread of ROS should improve outcome from TBI. Here a highly versatile, reproducible, and scalable method to synthesize core-cross-linked nanoparticles (NPs) from polysorbate 80 (PS80) using a combination of thiol–ene and thiol–Michael chemistry is described. The resultant NPs consist of a ROS-reactive thioether cross-linked core stabilized in aqueous solution by hydroxy-functional oligoethylene oxide segments. These NPs show narrow molecular weight distributions and have a high proportion of thioether units that reduce local levels of ROS. In a controlled cortical impact mouse model of TBI, the NPs are able to rapidly accumulate and be retained in damaged brain as visualized through fluorescence imaging, reduce neuroinflammation and the secondary spread of injury as determined through magnetic resonance imaging and histopathology, and improve functional outcome as determined through behavioral analyses. Our findings provide strong evidence that these NPs may, upon further development and testing, provide a useful strategy to help improve the outcome of patients following a TBI.
- 16 August 2017
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 11 (9) , 8600-8611
Core-Cross-Linked Nanoparticles Reduce Neuroinflammation and Improve Outcome in a Mouse Model of Traumatic Brain Injury
Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults, yet there are currently no treatments available that prevent the secondary spread of damage beyond the initial insult. The chronic progression of this secondary injury is in part caused by the release of reactive oxygen species (ROS) into surrounding normal brain. Thus, treatments that can enter the brain and reduce the spread of ROS should improve outcome from TBI. Here a highly versatile, reproducible, and scalable method to synthesize core-cross-linked nanoparticles (NPs) from polysorbate 80 (PS80) using a combination of thiol–ene and thiol–Michael chemistry is described. The resultant NPs consist of a ROS-reactive thioether cross-linked core stabilized in aqueous solution by hydroxy-functional oligoethylene oxide segments. These NPs show narrow molecular weight distributions and have a high proportion of thioether units that reduce local levels of ROS. In a controlled cortical impact mouse model of TBI, the NPs are able to rapidly accumulate and be retained in damaged brain as visualized through fluorescence imaging, reduce neuroinflammation and the secondary spread of injury as determined through magnetic resonance imaging and histopathology, and improve functional outcome as determined through behavioral analyses. Our findings provide strong evidence that these NPs may, upon further development and testing, provide a useful strategy to help improve the outcome of patients following a TBI.
- 9 May 2017
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 14 (6) , 1988-1997
Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections
Lung-based intracellular bacterial infections remain one of the most challenging infectious disease settings. For example, the current standard for treating Franciscella tularensis pneumonia (tularemia) relies on administration of oral or intravenous antibiotics that poorly achieve and sustain pulmonary drug bioavailability. Inhalable antibiotic formulations are approved and in clinical development for upper respiratory infections, but sustained drug dosing from inhaled antibiotics against alveolar intracellular infections remains a current unmet need. To provide an extended therapy against alveolar intracellular infections, we have developed a macromolecular therapeutic platform that provides sustained local delivery of ciprofloxacin with controlled dosing profiles. Synthesized using RAFT polymerization, these macromolecular prodrugs characteristically have high drug loading (16–17 wt % drug), tunable hydrolysis kinetics mediated by drug linkage chemistry (slow-releasing alkyllic vs fast-releasing phenolic esters), and, in general, represent new fully synthetic nanotherapeutics with streamlined manufacturing profiles. In aerosolized and completely lethal F.t. novicida mouse challenge models, the fast-releasing ciprofloxacin macromolecular prodrug provided high cure efficiencies (75% survival rate under therapeutic treatment), and the importance of release kinetics was demonstrated by the inactivity of the similar but slow-releasing prodrug system. Pharmacokinetics and biodistribution studies further demonstrated that the efficacious fast-releasing prodrug retained drug dosing in the lung above the MIC over a 48 h period with corresponding Cmax/MIC and AUC0–24h/MIC ratios being greater than 10 and 125, respectively; the thresholds for optimal bactericidal efficacy. These findings identify the macromolecular prodrug platform as a potential therapeutic system to better treat alveolar intracellular infections such as F. tularensis, where positive patient outcomes require tailored antibiotic pharmacokinetic and treatment profiles.
- 9 May 2017
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 14 (6) , 1988-1997
Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections
Lung-based intracellular bacterial infections remain one of the most challenging infectious disease settings. For example, the current standard for treating Franciscella tularensis pneumonia (tularemia) relies on administration of oral or intravenous antibiotics that poorly achieve and sustain pulmonary drug bioavailability. Inhalable antibiotic formulations are approved and in clinical development for upper respiratory infections, but sustained drug dosing from inhaled antibiotics against alveolar intracellular infections remains a current unmet need. To provide an extended therapy against alveolar intracellular infections, we have developed a macromolecular therapeutic platform that provides sustained local delivery of ciprofloxacin with controlled dosing profiles. Synthesized using RAFT polymerization, these macromolecular prodrugs characteristically have high drug loading (16–17 wt % drug), tunable hydrolysis kinetics mediated by drug linkage chemistry (slow-releasing alkyllic vs fast-releasing phenolic esters), and, in general, represent new fully synthetic nanotherapeutics with streamlined manufacturing profiles. In aerosolized and completely lethal F.t. novicida mouse challenge models, the fast-releasing ciprofloxacin macromolecular prodrug provided high cure efficiencies (75% survival rate under therapeutic treatment), and the importance of release kinetics was demonstrated by the inactivity of the similar but slow-releasing prodrug system. Pharmacokinetics and biodistribution studies further demonstrated that the efficacious fast-releasing prodrug retained drug dosing in the lung above the MIC over a 48 h period with corresponding Cmax/MIC and AUC0–24h/MIC ratios being greater than 10 and 125, respectively; the thresholds for optimal bactericidal efficacy. These findings identify the macromolecular prodrug platform as a potential therapeutic system to better treat alveolar intracellular infections such as F. tularensis, where positive patient outcomes require tailored antibiotic pharmacokinetic and treatment profiles.
- Open Access
- 1 February 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24 (2) , 331-341
Glucocorticoid Cell Priming Enhances Transfection Outcomes in Adult Human Mesenchymal Stem Cells
- 1 February 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24 (2) , 331-341
Open AccessGlucocorticoid Cell Priming Enhances Transfection Outcomes in Adult Human Mesenchymal Stem Cells
- 25 November 2015
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 7 (4) , 826-837
RAFT polymerization of ciprofloxacin prodrug monomers for the controlled intracellular delivery of antibiotics
Prodrug monomers derived from the antibiotic ciprofloxacin were synthesized with phenolic or aliphatic esters linking the drug to a polymerizable methacrylate group. RAFT polymerization of these monomers exhibited linear pseudo-first-order kinetics and Mnvs. conversion plots, and low Đ values throughout the polymerization. Prodrug monomers were then copolymerized with polyethyleneglycol methacrylate to yield hydrophilic copolymers with narrow Đ values. A poly(O950) macroCTA was also synthesized and chain extended with the antibiotic monomers to form diblock copolymers. The resultant copolymers and diblock copolymers were characterized with 1H and 19F NMR and found to contain 16.5 and 30–35 wt% ciprofloxacin, respectively. DLS measurements demonstrated that the copolymers remained unimeric between pH 5.6–7.4, while the diblock copolymers formed nanoparticles with diameters between 30–40 nm at physiological pH. Drug release kinetics were measured in human serum via HPLC analysis. Copolymers containing ciprofloxacin linked via phenolic esters showed faster hydrolysis rates with 50% drug released at 120 h, whereas copolymers with the corresponding aliphatic ester linkages showed the same drug release over 22 d. Diblock copolymers with a discrete ciprofloxacin block and a poly(O950) stabilizing block self-assembled into micelles, and exhibited reduced hydrolysis rates for both ester linked drugs. In vitro toxicity measurements in RAW 264.7 cells showed the copolymers to be nontoxic up to 20 mg mL−1 following a 24 h incubation period. The polymer drugs were shown to be active against Burkholderia thailandensis in a bacteria-macrophage co-culture model of melioidosis with MIC values of 6.0 and 0.6 mM for the aliphatic and phenyl ester linked copolymeric prodrugs, respectively.
- 25 November 2015
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 7 (4) , 826-837
RAFT polymerization of ciprofloxacin prodrug monomers for the controlled intracellular delivery of antibiotics
Prodrug monomers derived from the antibiotic ciprofloxacin were synthesized with phenolic or aliphatic esters linking the drug to a polymerizable methacrylate group. RAFT polymerization of these monomers exhibited linear pseudo-first-order kinetics and Mnvs. conversion plots, and low Đ values throughout the polymerization. Prodrug monomers were then copolymerized with polyethyleneglycol methacrylate to yield hydrophilic copolymers with narrow Đ values. A poly(O950) macroCTA was also synthesized and chain extended with the antibiotic monomers to form diblock copolymers. The resultant copolymers and diblock copolymers were characterized with 1H and 19F NMR and found to contain 16.5 and 30–35 wt% ciprofloxacin, respectively. DLS measurements demonstrated that the copolymers remained unimeric between pH 5.6–7.4, while the diblock copolymers formed nanoparticles with diameters between 30–40 nm at physiological pH. Drug release kinetics were measured in human serum via HPLC analysis. Copolymers containing ciprofloxacin linked via phenolic esters showed faster hydrolysis rates with 50% drug released at 120 h, whereas copolymers with the corresponding aliphatic ester linkages showed the same drug release over 22 d. Diblock copolymers with a discrete ciprofloxacin block and a poly(O950) stabilizing block self-assembled into micelles, and exhibited reduced hydrolysis rates for both ester linked drugs. In vitro toxicity measurements in RAW 264.7 cells showed the copolymers to be nontoxic up to 20 mg mL−1 following a 24 h incubation period. The polymer drugs were shown to be active against Burkholderia thailandensis in a bacteria-macrophage co-culture model of melioidosis with MIC values of 6.0 and 0.6 mM for the aliphatic and phenyl ester linked copolymeric prodrugs, respectively.
- Open Access
- 17 September 2014
- Published by Wiley in Physiological Reports
- Vol. 2 (9) , e12148
Surface-enhanced Raman spectral biomarkers correlate with Ankle Brachial Index and characterize leg muscle biochemical composition of patients with peripheral arterial disease
Peripheral arterial disease (PAD) is characterized by atherosclerotic blockages of the arteries supplying the lower extremities, which cause a progressive accumulation of ischemic injury to the skeletal muscles of the lower limbs. This injury includes altered metabolic processes, damaged organelles, and compromised bioenergetics in the affected muscles. The objective of this study was to explore the association of Raman spectral signatures of muscle biochemistry with the severity of atherosclerosis in the legs as determined by the Ankle Brachial Index (ABI) and clinical presentation. We collected muscle biopsies from the gastrocnemius (calf muscle) of five patients with clinically diagnosed claudication, five patients with clinically diagnosed critical limb ischemia (CLI), and five control patients who did not have PAD. A partial least squares regression (PLSR) model was able to predict patient ABI with a correlation coefficient of 0.99 during training and a correlation coefficient of 0.85 using a full cross‐validation. When using the first three PLS factor scores in combination with linear discriminant analysis, the discriminant model was able to correctly classify the control, claudicating, and CLI patients with 100% accuracy, using a full cross‐validation procedure. Raman spectroscopy is capable of detecting and measuring unique biochemical signatures of skeletal muscle. These signatures can discriminate control muscles from PAD muscles and correlate with the ABI and clinical presentation of the PAD patient. Raman spectroscopy provides novel spectral biomarkers that may complement existing methods for diagnosis and monitoring treatment of PAD patients.
- 17 September 2014
- Published by Wiley in Physiological Reports
- Vol. 2 (9) , e12148
Open AccessSurface-enhanced Raman spectral biomarkers correlate with Ankle Brachial Index and characterize leg muscle biochemical composition of patients with peripheral arterial disease
Peripheral arterial disease (PAD) is characterized by atherosclerotic blockages of the arteries supplying the lower extremities, which cause a progressive accumulation of ischemic injury to the skeletal muscles of the lower limbs. This injury includes altered metabolic processes, damaged organelles, and compromised bioenergetics in the affected muscles. The objective of this study was to explore the association of Raman spectral signatures of muscle biochemistry with the severity of atherosclerosis in the legs as determined by the Ankle Brachial Index (ABI) and clinical presentation. We collected muscle biopsies from the gastrocnemius (calf muscle) of five patients with clinically diagnosed claudication, five patients with clinically diagnosed critical limb ischemia (CLI), and five control patients who did not have PAD. A partial least squares regression (PLSR) model was able to predict patient ABI with a correlation coefficient of 0.99 during training and a correlation coefficient of 0.85 using a full cross‐validation. When using the first three PLS factor scores in combination with linear discriminant analysis, the discriminant model was able to correctly classify the control, claudicating, and CLI patients with 100% accuracy, using a full cross‐validation procedure. Raman spectroscopy is capable of detecting and measuring unique biochemical signatures of skeletal muscle. These signatures can discriminate control muscles from PAD muscles and correlate with the ABI and clinical presentation of the PAD patient. Raman spectroscopy provides novel spectral biomarkers that may complement existing methods for diagnosis and monitoring treatment of PAD patients.